Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib hydrochloride
Drug ID BADD_D01688
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 11525740
TTD Drug ID Not Available
NDC Product Code 68578-0015; 53104-7727; 0078-1077; 16436-0125; 63379-093; 54893-0014; 52482-015; 53296-0125; 62207-977; 68554-0058; 0078-0670; 76055-0050; 66499-0055
UNII 33Y9ANM545
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H24ClN7O2S
CAS Registry Number 635702-64-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hypertension24.08.02.001--
Hypothyroidism14.11.01.012; 05.02.03.001--
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Lymphopenia01.02.02.002--Not Available
Mucosal inflammation08.01.06.002--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Neutropenia01.02.03.004--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Palmar-plantar erythrodysaesthesia syndrome23.03.05.009; 17.02.07.009--
Proteinuria20.02.01.011--
Rash23.03.13.001--Not Available
Skin depigmentation23.05.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Skin hypopigmentation23.05.02.003--
Stomatitis07.05.06.005--
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Torsade de pointes02.03.04.005--Not Available
Tumour pain16.32.03.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Blood phosphorus decreased13.11.01.015--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages